Results 141 to 150 of about 47,659 (253)

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

The Construction and Application of a New Screening Method for Phosphodiesterase Inhibitors. [PDF]

Biosensors (Basel)
Gao C, Wang Z, Liu X, Sun R, Ma S, Ma Z, Wang Q, Li G, Zhang HT.   +8 more
europepmc   +1 more source

The effect of two phosphodiesterase inhibitors on bone healing in mandibular fractures (animal study in rats). [PDF]

J Korean Assoc Oral Maxillofac Surg, 2020
MalekiGorji M, Golestaneh A, Razavi SM.
europepmc   +1 more source

Atrial natriuretic peptide counteracts aldosterone secretion by preventing acute angiotensin II‐induced cAMP signalling

British Journal of Pharmacology, EarlyView.
Background and Purpose Aldosterone plays a key role in blood pressure and volume regulation. Enhanced aldosterone secretion contributes to cardiovascular and renal diseases. Therefore, inhibitors of aldosterone receptors and synthase are essential drugs for the treatment of hypertension and heart failure.
Sanika Mohagaonkar, Egor B. Skryabin, Bettina M. Buchholz, Michaela Kuhn, Celso E. Gomez‐Sanchez, Stepan Gambaryan, Viacheslav O. Nikolaev   +6 more
wiley   +1 more source

The use of phosphodiesterase inhibitors in the treatment of female sexual dysfunction: scoping review. [PDF]

Rev Bras Ginecol Obstet
Martins JCC, Lucas ARCA, Costa JMM.
europepmc   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

British Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo, Veronica Casale, Roberta d'Emmanuele di Villa Bianca, Valentina Vellecco, Mariarosaria Bucci   +4 more
wiley   +1 more source

Phosphodiesterase Inhibitors in Fetal Growth Restriction: Do Not Forget to Consider Fetal Sex and Subcellular Compartmentation. [PDF]

Biomedicines
Peyter AC, Baud D, Tolsa JF.
europepmc   +1 more source

The Role of Phosphodiesterase Inhibitors in the Management of Cavernositis With Multifocal Abscesses: A Report of Case Series. [PDF]

Sex Med, 2020
Bakhsh A, Daqqaq T, Alhasan A, Alnazari M, Rajih E.   +4 more
europepmc   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

The Role of 5-Phosphodiesterase Inhibitors (PDE-5I) in Current Benign Prostatic Hyperplasia Treatment: A Narrative Review. [PDF]

Medicina (Kaunas)
Stamatiou K, Perletti G, Magri V, Trinchieri A.   +3 more
europepmc   +1 more source